Glaukos Corporation · NYSE:GKOS

Glaukos — Investor Presentation (March 2017)

15 slides from Glaukos's investor presentation, Mar 10, 2017

  1. Slide 1: Disclaimer

    2 © 2017 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe th

  2. Slide 2: Transforming glaucoma therapy

    glaucoma therapy and highly successful launch global opportunity1 of current treatments of micro-scale 3 © 2017 Glaukos Corporation. istransforming LARGE MARKETUNMET NEEDDEMONSTRATED EXECUTIONJUST THE BEGINNING Growing $5bnSignificant drawbacksBroad reimbursementAdvanced portfolio injectable therapi

  3. Slide 3: 2016 Major Accomplishments

    4 © 2017 Glaukos Corporation. 2016Major Accomplishments 1.Reported 60% YoY global net sales growth versus 2015; exceeded U.S. surgeon training targets 2.Delivered 14th consecutive quarter of > 40% YoY growth since U.S. commercialization 3.Achieved gross margin in mid-80% range 4.Added Anthem and Tri

  4. Slide 4: Reducing IOP is the only proven treatment for glaucoma

    Reducing treatment IOP is the only proven for glaucoma 3 intraocular pressure (IOP) 1 OAG 2016 2021 increase from 83mm in 2016 to 2016 2021 Open-Angle Glaucoma All Glaucoma 5 © 2017 Glaukos Corporation. Aging Population Drives Glaucoma Prevalence US GLAUCOMA POPULATION1 (in millions) 5 4 Typically a

  5. Slide 5: How The Eye's Drainage System Works

    © 2017 Glaukos Corporation. 6 How The Eye’s Drainage System Works Elevated IOP occurs whenSecondary outflow pathway is aqueous humor outflow throughthe suprachoroidal space the trabecular meshwork and into Schlemm’s canal is reduced due to degeneration and obstruction

  6. Slide 6: iStent vs. Conventional Surgery

    © 2017 Glaukos Corporation. 7 iStent® vs. Conventional Surgery Conventional Surgery

  7. Slide 7: Compelling Clinical Results: Single iStent + Cataract Surgery Through 3 Years

    AT 36 MONTHS… CONSISTENT COHORT THROUGH 3 YEARS (n=39) 24 Preop Month 12 Month 24 Month 36 86% decision to implant based on eyes followed through 36 mean number of 9 Mean IOP (mm Hg) © 2017 Glaukos Corporation. Compelling Clinical Results: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through

  8. Slide 8: Compelling Clinical Results: US Retrospective Studies of Single iStent

    20 16.37 15.17 13.6 16 Preop 1M 6M 12M 18M 24M Group 3: IOP not controlled Group 2: IOP not controlled Group 1: IOP controlled 10 Mean IOP (mm Hg) Mean IOP (mm Hg) © 2017 Glaukos Corporation. Compelling Clinical Results: US Retrospective Studies of Single iStent + Cataract Surgery MEAN IOPMEAN IOP T

  9. Slide 9: Compelling Clinical Results: International Study of 1, 2 and 3 iStents

    Demonstrates potential Medications 14.1 14 groups with preoperative in standalone Mean preop medicated Mean preop IOP after Month 18 mean IOP 11 mm Hg © 2017 Glaukos Corporation. Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Mean IOP at 18 Month

  10. Slide 10: Clinical Research Program Statistics

    21 Prospective clinical trials currently underway Articles published in journals 12 © 2017 Glaukos Corporation. Clinical Research Program Statistics 56 peer-reviewed

  11. Slide 11: Financial & Operational Performance: Growth Reflects iStent Adoption Trends

    $33.2 $35 least 40% year-over-year growth +64% Includes 215% growth in 13 © 2017 Glaukos Corporation. Q4 2016 Financial & Operational Performance: Growth Reflects iStent Adoption Trends TOTAL NET SALES (in millions) 14th consecutive quarter of at $30in net sales $25YoY $20international sales, compar

  12. Slide 12: Current & Future Potential MIGS Market Participants

    14 © 2017 Glaukos Corporation. Current & Future Potential MIGS Market Participants ALCON CYPASS 6.35mm suprachoroidal device for implantation into supraciliary space using guidewire delivery (actual) IVANTIS HYDRUS 8mm nitinol scaffolding device implanted into Schlemm’s canal (image) ALLERGAN XEN (F

  13. Slide 13: Financial Summary

    (IN MILLIONS) 0% and same-store sales global expansion 15 © 2017 Glaukos Corporation. Financial Summary NET SALESGROSS MARGIN Strong net sales growth, driven by increases in trained doctors oY Ability to leverage efficient manufacturing and cost structure Continued investments in pipeline developmen

  14. Slide 14: © 2017 Glaukos Corporation. 17

    © 2017 Glaukos Corporation. 17

  15. Slide 15: Glaukos MIGS

Glaukos — Investor Presentation (March 2017) on 6ix